Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mullen

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Scientific Reports|May 23, 2019
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031Awa Sarr, Jennifer Bré, In Hwa Um, et al.
Cancer Research|August 3, 2005
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancerKenneth Macleod, Peter Mullen, Jane Sewell, et al.
Npj Imaging|September 16, 2025
Kidney tumoroid characterisation by spatial mass spectrometry with same-section multiplex immunofluorescence uncovers tumour microenvironment lipid signatures associated with aggressive tumour phenotypesHazem Abdullah, Greice M Zickuhr, In Hwa Um, et al.
Cancer Treatment Reviews|October 16, 2012
New strategies for targeting the hypoxic tumour microenvironment in breast cancerCarol Ward, Simon P Langdon, Peter Mullen, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 26, 2016
Embedding a Panoramic Representation of Infrared Light in the Adult Rat Somatosensory Cortex through a Sensory NeuroprosthesisKonstantin Hartmann, Eric E Thomson, Ivan Zea, et al.
Carcinogenesis|December 8, 2005
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cellsFiona McPhillips, Peter Mullen, Kenneth G MacLeod, et al.
Cancer Research|August 5, 2008
Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivoKevin Morgan, Alan J Stewart, Nicola Miller, et al.
Plos One|April 20, 2012
Diversity of matriptase expression level and function in breast cancerArkadiusz Welman, Duncan Sproul, Peter Mullen, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2012
Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell linesJean-Yves Winum, Fabrizio Carta, Carol Ward, et al.
BMC Medicine|June 27, 2017
Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancerAlexander L R Lubbock, Grant D Stewart, Fiach C O'Mahony, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Scientific Reports|May 23, 2019
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031Awa Sarr, Jennifer Bré, In Hwa Um, et al.
Cancer Research|August 3, 2005
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancerKenneth Macleod, Peter Mullen, Jane Sewell, et al.
Npj Imaging|September 16, 2025
Kidney tumoroid characterisation by spatial mass spectrometry with same-section multiplex immunofluorescence uncovers tumour microenvironment lipid signatures associated with aggressive tumour phenotypesHazem Abdullah, Greice M Zickuhr, In Hwa Um, et al.
Cancer Treatment Reviews|October 16, 2012
New strategies for targeting the hypoxic tumour microenvironment in breast cancerCarol Ward, Simon P Langdon, Peter Mullen, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 26, 2016
Embedding a Panoramic Representation of Infrared Light in the Adult Rat Somatosensory Cortex through a Sensory NeuroprosthesisKonstantin Hartmann, Eric E Thomson, Ivan Zea, et al.
Carcinogenesis|December 8, 2005
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cellsFiona McPhillips, Peter Mullen, Kenneth G MacLeod, et al.
Cancer Research|August 5, 2008
Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivoKevin Morgan, Alan J Stewart, Nicola Miller, et al.
Plos One|April 20, 2012
Diversity of matriptase expression level and function in breast cancerArkadiusz Welman, Duncan Sproul, Peter Mullen, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2012
Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell linesJean-Yves Winum, Fabrizio Carta, Carol Ward, et al.
BMC Medicine|June 27, 2017
Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancerAlexander L R Lubbock, Grant D Stewart, Fiach C O'Mahony, et al.
Pageof 5